Corticotropin-releasing factor 1 (CRF1) receptor has been of considerable interest for the development of stress-related disorder treatment. We will describe the discovery and preclinical development of our clinical candidate, E2508, for the treatment of anxiety and depression.

Discovery of a novel, potent, selective, and orally active corticotropin-releasing factor 1 (CRF<sub>1</sub>) receptor antagonist, E2508, for the treatment of stress-related disorders such as anxiety and depression

244th National Meeting (2012)

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.

Discovery of a novel, potent, selective, and orally active corticotropin-releasing factor 1 (CRF1) receptor antagonist, E2508, for the treatment of stress-related disorders such as anxiety and depression

Discovery of a novel, potent, selective, and orally active corticotropin-releasing factor 1 (CRF₁) receptor antagonist, E2508, for the treatment of stress-related disorders such as anxiety and depression